, Risk and Clinical Implications of Transformation of Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Journal of Clinical Oncology, vol.25, issue.17, pp.2426-2433, 2007.
DOI : 10.1200/JCO.2006.09.3260
, Populationbased analysis of incidence and outcome of transformed non- Hodgkin's lymphoma, J Clin Oncol, vol.2616, pp.5165-5169, 2008.
, Incidence, risk factors and outcome of histological transformation in follicular lymphoma, British Journal of Haematology, vol.13, issue.2, pp.188-196, 2012.
DOI : 10.1111/j.1365-2141.2012.09054.x
, Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS), Blood, vol.126, issue.7, pp.851-857, 2015.
DOI : 10.1182/blood-2015-01-621375
, Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group, Blood, vol.106, issue.12, pp.3725-3732, 2005.
DOI : 10.1182/blood-2005-01-0016
, CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma, Blood, vol.105, issue.4, pp.1417-1423, 2005.
DOI : 10.1182/blood-2004-08-3175
, Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study, Journal of Clinical Oncology, vol.25, issue.15, pp.1986-1992, 2007.
DOI : 10.1200/JCO.2006.06.4618
, Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study, Blood, vol.112, issue.13, pp.4824-4831, 2008.
DOI : 10.1182/blood-2008-04-153189
, Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial, The Lancet, vol.377, issue.9759, pp.42-51, 2011.
DOI : 10.1016/S0140-6736(10)62175-7
, High-Dose Therapy Improves Progression-Free Survival and Survival in Relapsed Follicular Non-Hodgkin???s Lymphoma: Results From the Randomized European CUP Trial, Journal of Clinical Oncology, vol.21, issue.21, pp.3918-3927, 2003.
DOI : 10.1200/JCO.2003.10.023
, Impact of Rituximab and/or High-Dose Therapy With Autotransplant at Time of Relapse in Patients With Follicular Lymphoma: A GELA Study, Journal of Clinical Oncology, vol.26, issue.21, pp.3614-3620, 2008.
DOI : 10.1200/JCO.2007.15.5358
, Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage, Blood, vol.111, issue.8, pp.4004-4013, 2007.
DOI : 10.1182/blood-2007-10-116749
, Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study, Haematologica, vol.96, issue.8, pp.1128-1135, 2011.
DOI : 10.3324/haematol.2010.030320
, Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial, Blood, vol.108, issue.10, pp.3295-3301, 2006.
DOI : 10.1182/blood-2006-05-021113
, Rituximab maintenance treatment of relapsed/resistant follicular non- Hodgkin's lymphoma: long-term outcome of the EORTC, 2010.